Author

Е. V. Lymar

Observed names: E. V. Lymar, E.V. Lymar, Е.В. Лымарь, Лымарь Елена Владимировна

Institution: State Clinical Hospital "Clinical Oncology Center No. 1

Observed institution: State Clinical Hospital "Clinical Oncology Center No. 1

ORCID: 0000-0002-6866-1425

Observed ORCID: 0000-0002-6866-1425

OpenAlex ID: A5023418983

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

2020 · E. V. Borodavina, P. A. Isaev, et al. · Head and neck tumors (HNT) · 6

PDF

Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study

2021 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 2

PDF

Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision

2023 · A. Yu. Goryainova, R. A. Murashko, et al. · Meditsinskiy sovet = Medical Council · 1

PDF

Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer

2022 · A. Yu. Goryainova, A. I. Stukan, et al. · Meditsinskiy sovet = Medical Council · 1

Experience with the use of trastuzumab deruxtecan in real-world clinical practice: data from Clinical Oncology Dispensary no. 1 (Krasnodar) and Federal Scientific Clinical Center of the fMBA of Russia

2026 · M. Yu. Mostovoy, S. V. Sharov, et al. · Academy for Practical Oncology

PDF

The Place of Targeted Therapy in Pretreated Patients with Metastatic Melanoma of the Skin: a Mini-Review and Clinical Observation

2026 · A.A. Kurmanaliev, E.V. Lymar, et al. · Effective Pharmacotherapy

Encorafenib and binimetinib in the treatment of metastatic melanoma

2026 · I.V. Rykov, A.R. Alekseeva, et al. · Russian Medical Inquiry

Induction of ovarian steroidogenesis as an additional potential risk factor for progression in premenopausal patients with hormone-receptor-positive breast cancer receiving tamoxifen as adjuvant therapy

2022 · A. Yu. Goryainova, A. I. Stukan, et al. · Meditsinskiy sovet = Medical Council

PDF

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors

2021 · A. Yu. Goryainova, A. I. Stukan, et al. · Meditsinskiy sovet = Medical Council

PDF

Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?

2021 · A. I. Stukan, A. Y. Goryainova, et al. · Meditsinskiy sovet = Medical Council

PDF

Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease

2021 · A. I. Stukan, A. Yu. Goryainova, et al. · Meditsinskiy sovet = Medical Council

PDF

Mechanisms of metastasis and development of resistance to therapy in breast cancer. A clinical case of the effectiveness of ixabepilone in hormone-receptorpositive breast cancer with multidrug resistance

2021 · A. I. Stukan, A. Y. Goryainova, et al. · Meditsinskiy sovet = Medical Council

PDF

Analysis of the clinical efficacy of the cyclin- dependent kinase inhibitor 4/6 Abemaciclib on the clinical case of a male with hormonereceptor- positive breast cancer

2021 · А. Y. Goryainova, А. I. Stukan, et al. · Meditsinskiy sovet = Medical Council

PDF

Анализ Клинической Эффективности Ингибитора Циклин-зависимых Киназ 4/6 Абемациклиба На Примере Лечения Пациента С Гормон- Рецепторпозитивным Раком Молочной Железы

2021 · А. Ю. Горяинова, А. I. Stukan, et al. · Meditsinskiy sovet = Medical Council

Анализ региональной клинической практики применения CDK4/6 – ингибитора рибоциклиба как механизм интеграции научно-исследовательского подхода в организацию лекарственного обеспечения

· Горяинова Алла Юрьевна, Мурашко Роман Алексеевич, et al. · CyberLeninK (CyberLeninka)

Works count: 16

Citation count: 10

H-index: 2

I10-index: